 This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone iPTH and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients. 